October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Emad Sedeek: PGT-A Is a Diagnostic Tool, Not a Guaranteed Pathway to Higher IVF Success

Emad Sedeek/brainscape.com

Jul 10, 2026, 13:28

Emad Sedeek: PGT-A Is a Diagnostic Tool, Not a Guaranteed Pathway to Higher IVF Success

Emad Sedeek, IVF Lab Director at New Hope IVF, shared a post on LinkedIn:

“PGT-A in Routine Practice: What the Largest Real-World Dataset Actually Shows:

A new analysis of 111,975 UK IVF (HFEA register, 2014–2018), correcting a well-known immortal time bias present in earlier work found that:
PGT-A was associated with a reduced, not improved, live birth rate: (OR 0.86 in the first transfer) and (0.74 cumulatively, compared with standard IVF).
This matters because it reconciles real-world data with what randomized trials (STAR, Yan et al. NEJM 2021, Ozgur et al.) have shown for years: PGT-A does not increase the chance of a live birth when used as an embryo-selection tool.

Where it may offer value is in reducing pregnancy loss per pregnancy

a benefit worth discussing with patients who prioritize avoiding miscarriage over maximizing overall live birth chances.
As embryologists, our responsibility is to counsel patients with the evidence as it stands, not as marketing narratives present it.
PGT-A is a diagnostic tool with a specific, limited role, not a guaranteed pathway to a higher success rate.
Evidence-based counselling protects patient trust and that’s non-negotiable in our field.

In my view, cost-effectiveness needs to be carefully considered, along with avoiding overuse of the technique, and relying more on evidence-based outcomes.
Some indicated cases, not all, benefit from PGT-A. Therefore, tools should be used in their appropriate context, and this is one of the most important benefits science provides.”

Proceed to the pages attached to the post.

Stay updated on all scientific advances in the field of fertility with Fertility News.